Whalen v. Bayer Corp.
Supreme Court of Pennsylvania
Whalen v. Bayer Corp., 36 A.3d 587 (Pa. 2012)
614 Pa. 309; 2012 WL 284519; 2012 Pa. LEXIS 212
Per Curiam
Whalen v. Bayer Corp.
Opinion
ORDER
AND NOW, this 1st day of February, 2012, as Petitioners’ Amended Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction replaced the initial Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction, the initial Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction is DISMISSED. Additionally, the Motion for Leave to File Reply Brief and the Motion for Leave to Supplement Application are GRANTED. *310 Furthermore, the Amended Application for Exercise of King’s Bench Powers or Extraordinary Jurisdiction is DENIED. Finally, the Motion for Consolidation is DISMISSED AS MOOT.
Reference
- Full Case Name
- Rachel WHALEN, Respondent v. BAYER CORPORATION, Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., F/K/A Berlex, Inc., F/K/A Berlex Laboratories, Inc. on Its Own Behalf and as Successor by Merger to Bayer Pharmaceuticals Corporation, and Bayer Pharma AG, F/K/A Bayer Schering Pharma AG, Petitioners
- Status
- Published